Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BDKRB1 | P46663 | 18/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28781515 | 0.88 | BDKRB1 (0.79) | BDKRB1 | |
| SCHEMBL28625 | 0.86 | BDKRB1 (0.76) | BDKRB1 | |
| SCHEMBL31305 | 0.85 | BDKRB1 (0.72) | BDKRB1 | |
| SCHEMBL27995 | 0.84 | ALDH1A1 (0.74) | BDKRB1 | |
| SCHEMBL3041146 | 0.82 | BDKRB1 (0.70) | BDKRB1 | |
| SCHEMBL5095180 | 0.81 | BDKRB1 (0.68) | BDKRB1 | |
| SCHEMBL2534648 | 0.81 | BDKRB1 (0.73) | BDKRB1 | |
| SCHEMBL1970717 | 0.81 | BDKRB1 (0.71) | BDKRB1 | |
| SCHEMBL5100609 | 0.80 | BDKRB1 (0.67) | BDKRB1 | |
| SCHEMBL14131252 | 0.80 | MEN1 (0.77) | BDKRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7393873-B2 | Arylsulfonamide derivatives | MERCK & CO., INC. (US) | 2008-07-01 | — | — | US | disclosed |
| US-7393873-B2 | Arylsulfonamide derivatives | MERCK & CO., INC. (US) | 2008-07-01 | — | — | US | disclosed |
| US-20060142612-A1 | Arylsulfonamide derivatives | MERCK SHARP & DOHME CORP. | 2006-06-29 | — | — | US | disclosed |
| EP-1643960-A2 | ARYLSULFONAMIDE DERIVATIVES | Merck & Co., Inc. (US) | 2006-04-12 | — | — | EP | disclosed |
| WO-2005004810-A2 | ARYLSULFONAMIDE DERIVATIVES | MERCK & CO., INC. (US) | 2005-01-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060142612-A1 | Arylsulfonamide derivatives | BDKRB1, BDKRB2, LTB4R2 | BDKRB1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.